494 related articles for article (PubMed ID: 11319908)
61. Overexpression of the fanconi anemia group C gene (FAC) protects hematopoietic progenitors from death induced by Fas-mediated apoptosis.
Wang J; Otsuki T; Youssoufian H; Foe JL; Kim S; Devetten M; Yu J; Li Y; Dunn D; Liu JM
Cancer Res; 1998 Aug; 58(16):3538-41. PubMed ID: 9721856
[TBL] [Abstract][Full Text] [Related]
62. Fanconi anemia C protein acts at a switch between apoptosis and necrosis in mitomycin C-induced cell death.
Guillouf C; Wang TS; Liu J; Walsh CE; Poirier GG; Moustacchi E; Rosselli F
Exp Cell Res; 1999 Feb; 246(2):384-94. PubMed ID: 9925754
[TBL] [Abstract][Full Text] [Related]
63. Lentivirus-mediated gene transfer in primary T cells is enhanced by a central DNA flap.
Dardalhon V; Herpers B; Noraz N; Pflumio F; Guetard D; Leveau C; Dubart-Kupperschmitt A; Charneau P; Taylor N
Gene Ther; 2001 Feb; 8(3):190-8. PubMed ID: 11313790
[TBL] [Abstract][Full Text] [Related]
64. Phenotypic correction of Fanconi anemia group C knockout mice.
Gush KA; Fu KL; Grompe M; Walsh CE
Blood; 2000 Jan; 95(2):700-4. PubMed ID: 10627482
[TBL] [Abstract][Full Text] [Related]
65. Stem Cell Genetic Therapy for Fanconi Anemia - A New Hope.
Hanenberg H; Roellecke K; Wiek C
Curr Gene Ther; 2017; 16(5):309-320. PubMed ID: 28067166
[TBL] [Abstract][Full Text] [Related]
66. The Fanconi anemia complementation group C gene (FAC) suppresses transformation of mutant fibroblasts by the SV40 virus.
Liu JM; Poiley J; Devetten M; Kajigaya S; Walsh CE
Biochem Biophys Res Commun; 1996 Jun; 223(3):685-90. PubMed ID: 8687457
[TBL] [Abstract][Full Text] [Related]
67. Use of HIV as a gene transfer vector.
Pluta K; Kacprzak MM
Acta Biochim Pol; 2009; 56(4):531-95. PubMed ID: 19936329
[TBL] [Abstract][Full Text] [Related]
68. Comparison of gene transfer efficiencies and gene expression levels achieved with equine infectious anemia virus- and human immunodeficiency virus type 1-derived lentivirus vectors.
O'Rourke JP; Newbound GC; Kohn DB; Olsen JC; Bunnell BA
J Virol; 2002 Feb; 76(3):1510-5. PubMed ID: 11773424
[TBL] [Abstract][Full Text] [Related]
69. Damage-resistant DNA synthesis in Fanconi anemia cells treated with a DNA cross-linking agent.
Centurion SA; Kuo HR; Lambert WC
Exp Cell Res; 2000 Nov; 260(2):216-21. PubMed ID: 11035916
[TBL] [Abstract][Full Text] [Related]
70. Preclinical correction of human Fanconi anemia complementation group A bone marrow cells using a safety-modified lentiviral vector.
Becker PS; Taylor JA; Trobridge GD; Zhao X; Beard BC; Chien S; Adair J; Kohn DB; Wagner JE; Shimamura A; Kiem HP
Gene Ther; 2010 Oct; 17(10):1244-52. PubMed ID: 20485382
[TBL] [Abstract][Full Text] [Related]
71. Intracellular localization of the Fanconi anemia complementation group A protein.
Walsh CE; Yountz MR; Simpson DA
Biochem Biophys Res Commun; 1999 Jun; 259(3):594-9. PubMed ID: 10364463
[TBL] [Abstract][Full Text] [Related]
72. The efficiency of simian foamy virus vector type-1 (SFV-1) in nondividing cells and in human PBLs.
Mergia A; Chari S; Kolson DL; Goodenow MM; Ciccarone T
Virology; 2001 Feb; 280(2):243-52. PubMed ID: 11162838
[TBL] [Abstract][Full Text] [Related]
73. Progress towards hematopoietic stem cell gene therapy.
Kurre P; Kiem HP
Curr Opin Mol Ther; 2000 Aug; 2(4):400-11. PubMed ID: 11249770
[TBL] [Abstract][Full Text] [Related]
74. Clinical variability of Fanconi anemia (type C) results from expression of an amino terminal truncated Fanconi anemia complementation group C polypeptide with partial activity.
Yamashita T; Wu N; Kupfer G; Corless C; Joenje H; Grompe M; D'Andrea AD
Blood; 1996 May; 87(10):4424-32. PubMed ID: 8639804
[TBL] [Abstract][Full Text] [Related]
75. Lentiviral-Mediated Gene Therapy in Fanconi Anemia-A Mice Reveals Long-Term Engraftment and Continuous Turnover of Corrected HSCs.
Molina-Estevez FJ; Nowrouzi A; Lozano ML; Galy A; Charrier S; von Kalle C; Guenechea G; Bueren JA; Schmidt M
Curr Gene Ther; 2015; 15(6):550-62. PubMed ID: 26415575
[TBL] [Abstract][Full Text] [Related]
76. Four novel mutations of the Fanconi anemia group A gene (FAA) in Japanese patients.
Nakamura A; Matsuura S; Tauchi H; Hanada R; Ohashi H; Hasegawa T; Honda K; Masuno M; Imaizumi K; Sugita K; Ide T; Komatsu K
J Hum Genet; 1999; 44(1):48-51. PubMed ID: 9929978
[TBL] [Abstract][Full Text] [Related]
77. [Improvements of lentiviral vector and its application in gene therapy of hematological diseases].
Zhu HH; Xu KL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Apr; 11(2):208-12. PubMed ID: 12744751
[TBL] [Abstract][Full Text] [Related]
78. [Progress of research on protein composition and gene therapy of Fanconi anaemia - review].
Li ZY; Zou YF; Deng YB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Apr; 12(2):231-5. PubMed ID: 15157341
[TBL] [Abstract][Full Text] [Related]
79. MxA overexpression reveals a common genetic link in four Fanconi anemia complementation groups.
Li Y; Youssoufian H
J Clin Invest; 1997 Dec; 100(11):2873-80. PubMed ID: 9389754
[TBL] [Abstract][Full Text] [Related]
80. Inactivation of the Fanconi anemia group C gene augments interferon-gamma-induced apoptotic responses in hematopoietic cells.
Rathbun RK; Faulkner GR; Ostroski MH; Christianson TA; Hughes G; Jones G; Cahn R; Maziarz R; Royle G; Keeble W; Heinrich MC; Grompe M; Tower PA; Bagby GC
Blood; 1997 Aug; 90(3):974-85. PubMed ID: 9242526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
